Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 4/20 | 0.51 |
| ▸ | DRD5 | P21918 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16807896 | 0.99 | DRD1 (0.52) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| SCHEMBL14199982 | 0.81 | DRD1 (0.75) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Bromide SCHEMBL11712496 | 0.78 | KDM4E (0.68) | DRD1CYP2D6DRD2HSD17B10THPO | |
| SCHEMBL460269 | 0.78 | DRD1 (0.64) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| SCHEMBL11543046 | 0.77 | CYP3A4 (0.69) | CYP2D6CYP3A4 | |
| SCHEMBL14288500 | 0.77 | SIGMAR1 (0.56) | SIGMAR1LMNA | |
| SCHEMBL462798 | 0.76 | DRD1 (0.65) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| SCHEMBL10800464 | 0.75 | CYP3A4 (0.52) | CYP2D6CYP3A4 | |
| SCHEMBL11105580 | 0.74 | DRD1 (0.61) | DRD1DRD5CYP1A2CYP2D6DRD2 | |
| Bromide SCHEMBL11721722 | 0.73 | KDM4E (0.71) | DRD1DRD5CYP2D6DRD2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949983-B2 | Fused benzazepines for treatment of stuttering | PSYADON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals ,Inc. | 2016-09-22 | — | — | US | disclosed |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | HORIZON TECHNOLOGY FINANCE CORPORATION | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | TACR1, AVPR1A, AVPR1B | DRD1 28/4885DRD5 40/4885CYP1A2 704/4885 |
| US-20150164911-A1 | Fused Benzazepines for Treatment of Tourette's Syndrome | COMT, SLC6A3, HTR3A | DRD1 30/4885DRD5 39/4885CYP1A2 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.